Back to Search
Start Over
Inhibition of Cathepsin K for Treatment of Osteoporosis.
- Source :
- Current Osteoporosis Reports; Mar2012, Vol. 10 Issue 1, p73-79, 7p
- Publication Year :
- 2012
-
Abstract
- Cathepsin K is the protease that is primarily responsible for the degradation of bone matrix by osteoclasts. Inhibitors of cathepsin K are in development for treatment of osteoporosis. Currently available antiresorptive drugs interfere with osteoclast function. They inhibit both bone resorption and formation, due to the coupling between these processes. Cathepsin K inhibitors, conversely, target the resorption process itself and may not interfere with osteoclast stimulation of bone formation. In fact, when cathepsin K is absent or inhibited in mice, rabbits, or monkeys, bone formation is maintained or increased. In humans, inhibition of cathepsin K is associated with sustained reductions in bone resorption markers but with smaller and transient reductions in bone formation markers. The usefulness of cathepsin K inhibitors in osteoporosis is now being examined in phase 2 and phase 3 clinical trials of postmenopausal osteoporotic women. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15441873
- Volume :
- 10
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Current Osteoporosis Reports
- Publication Type :
- Academic Journal
- Accession number :
- 71814336
- Full Text :
- https://doi.org/10.1007/s11914-011-0085-9